Trials & Filings
Related Searches:
Filter by:
61 - 75 of 604 results
December 6, 2010
Pfizer achieved positive results from a Phase III study of the investigational compound bosutinib as a first-line treatment in patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).
Read More »
December 6, 2010
Genentech, a member of the Roche Group, achieved positive results from a Phase II study of RG16781, an investigational glycine reuptake inhibitor (GRI) for the treatment of schizophrenia.
Read More »
December 2, 2010
Applied Pharma Research (APR) and its partner Labtec, a drug delivery developer, have submitted Zolmitriptan Oral Dispersible Film (ODF) for approval in Europe.
Read More »
November 29, 2010
Pfizer and Protalix BioTherapeutics have submitted a Marketing Authorization Application to the EMA for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD), for the treatment of Gaucher disease.
Read More »
November 24, 2010
Eli Lilly and Co. and Acrux received approval from the FDA for Axiron (testosterone) topical solution CIII for replacement therapy in men for conditions associated with a deficiency or absence of testosterone.
Read More »
November 23, 2010
Abbott achieved positive results from a Phase II dose-ranging study of atrasentan, a highly selective endothelin A receptor antagonist in development to help slow chronic kidney disease (CKD) progression in patients with type 2 diabetic kidney disease.
Read More »
November 22, 2010
Regeneron Pharmaceuticals, Inc. and Bayer HealthCare achieved positive results from two parallel Phase III studies in patients with the neovascular form of age-related macular degeneration (wet AMD), with all regimens of VEGF Trap-Eye (aflibercept ophthal
Read More »
November 19, 2010
Amgen received approval from the FDA for XGEVA (denosumab), the first RANK Ligand inhibitor for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors.
Read More »
November 19, 2010
Pfizer’s Phase III trial studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC) met its primary endpoint, demonstrating significantly extended progression-free survival (PFS) when co
Read More »
November 16, 2010
Halaven injection adds new option in metastatic breast cancer
Read More »
November 11, 2010
Centocor Ortho Biotech, Inc. has submitted an sBLA to the FDA to expand the Simponi label to include the inhibition of the progression of structural damage and maintenance of signs and symptoms of active psoriatic arthritis (PsA).
Read More »
November 8, 2010
Bristol-Myers Squibb and AstraZeneca received approval from the FDA for Kombiglyze XR for the treatment of type 2 diabetes in adults.
Read More »
November 5, 2010
Eli Lilly and Co. received approval from the FDA for Cymbalta (duloxetine HCl) for the management of chronic musculoskeletal pain.
Read More »
November 5, 2010
Genentech achieved positive results from a Phase II study of RG7204, an investigational molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half of metastatic melanoma tumors.
Read More »
November 4, 2010
Millennium, The Takeda Oncology Company, has initiated a Phase III trial for TAK-700 in patients with advanced prostate cancer.
Read More »
61 - 75 of 604 results
